sofosbuvir + pegylated interferon alfa-2a + ribavirin

This is a **triple combination therapy** used to treat chronic hepatitis C virus (HCV) infection, especially genotypes 1 and 4. - **Sofosbuvir** is a nucleotide analog **NS5B polymerase inhibitor** that blocks HCV RNA replication. - **Pegylated interferon alfa-2a** is a **recombinant cytokine** that induces antiviral immune responses via the **interferon alpha receptor**, modulating immune activity and limiting viral replication. - **Ribavirin** is a **nucleoside analog** that broadly inhibits viral RNA synthesis and impairs viral genetic fidelity. This combination is used for 12 weeks in genotype 1 or 4 HCV and sometimes in genotype 1 patients who are interferon-eligible. Phase 3 clinical data confirm superior efficacy compared to historical controls, with sustained virologic response (SVR) rates around 90% for 12 weeks of therapy. The combination is **approved for use** in the United States for HCV genotypes 1 and 4, and is recommended in patients with or without cirrhosis, but **is not recommended for patients with severe renal impairment or decompensated liver disease**. Most common adverse effects are fatigue, headache, nausea, insomnia, and anemia[1][3][4].

Brand names

Sovaldi + Pegasys + Copegus

Other names

sofosbuvir + peginterferon alfa-2a + ribavirin